Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | SAT1 | P21673 | 3/20 | 0.56 |
| ▸ | KDM1A | O60341 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172702 | 1.00 | CYP2C19 (0.81) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL5183955 | 0.97 | CYP2C19 (0.82) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL30520901 | 0.97 | CYP2C19 (0.77) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL13097540 | 0.94 | CYP2C19 (0.77) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL15884078 | 0.94 | CYP2C19 (0.77) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL24409456 | 0.94 | CYP2C19 (0.77) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL24672655 | 0.91 | CYP2C19 (0.72) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL2905152 | 0.90 | CYP2C19 (0.62) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL10904114 | 0.90 | CYP2C19 (0.62) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| Bis(Ethyl)Norspermine SCHEMBL429527 | 0.90 | CYP2C19 (1.00) | CYP2C19MEN1GLAKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| CN-105163730-A | Methods and compositions for treating demyelinating diseases | PATHOLOGICA LLC | 2015-12-16 | — | — | CN | disclosed |
| EP-2943189-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | Pathologica LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| CN-102686222-A | Orally delivered drugs comprising MGBG and methods of treating diseases | PATHOLOGICA LLC | 2012-09-19 | — | — | CN | disclosed |
| EP-2453886-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | Pathologica, LLC. (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-1177197-B1 | POLYAMINES AND THEIR USE IN THERAPY | CELLGATE INC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006041805-A1 | POLYAMINE ANALOGS AS THERAPEUTIC AGENTS FOR OCULAR DISEASES | CELLGATE, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| CN-1606694-A | Methods for monitoring and treating amyotrophic lateral sclerosis | SLIL BIOMEDICAL CORP (US) | 2005-04-13 | — | — | CN | disclosed |
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1296931-A2 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | MediQuest Therapeutics, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002091989-A2 | ANTIVIRAL THERAPIES USING POLYAMINE OR POLYAMINE ANALOG-AMINO ACID CONJUGATES | SLIL BIOMEDICAL CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2001072685-A9 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | ORIDIGM CORP (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1177197-A2 | POLYAMINES AND THEIR USE IN THERAPY | Slil Biomedical Corporation (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001072685-A2 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | ORIDIGM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000066587-A2 | POLYAMINES AND THEIR USE IN THERAPY | SLIL BIOMEDICAL CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | CYP2C19 3757/4885MEN1 177/4885GLA 4226/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | CYP2C19 4541/4885MEN1 401/4885GLA 137/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | CYP2C19 4252/4885MEN1 2868/4885GLA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.